(Q37213612)

19 August 2017

1 reference

title

Molecular mechanisms and therapeutic development of angiogenesis inhibitors (English)

1 reference

19 August 2017

main subject

angiogenesis inhibitor

1 reference

Yihai Cao

1

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Advances in Cancer Research

19 August 2017

published in

1 reference

19 August 2017

volume

100

1 reference

19 August 2017

page(s)

113-131

1 reference

Endostatin's antiangiogenic signaling network

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Insight into the physiological functions of PDGF through genetic studies in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Blockage of VEGF-induced angiogenesis by preventing VEGF secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

The hypoxic response of tumors is dependent on their microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Angiogenesis in life, disease and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Common mechanisms of nerve and blood vessel wiring

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Endothelial cells and VEGF in vascular development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Discovery of vascular permeability factor (VPF).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Looking for a good endothelial address

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Angiogenesis inhibitors suffer new setback

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

The second wave in kinase cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Tumor-associated endothelial cells with cytogenetic abnormalities.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Roles of PDGF in animal development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Circulating angiogenic factors and the risk of preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Notch signaling from tumor cells: a new mechanism of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Endogenous inhibitors of angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Polymeric system for dual growth factor delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2808%2900004-3

7 January 2021

10.1016/S0065-230X(08)00004-3

Identifiers

DOI

1 reference

19 August 2017

1 reference